Furthermore, our results suggest that pharmacological activation of CD36 or restoration of CD36 expression in the RPE of patients with dry AMD could be used therapeutically to prevent photoreceptor cell death by boosting SE renewal and to maintain a healthy choroid and retinal oxygenation by enhanced COX2 expression. Here, PTGS2 is linked to dry age related macular degeneration.